Chronic cystitis/interstitial cystitis
Conditions
Interventions
PRP Group:Autologous platelet-rich plasma (PRP) submucosal injection into the bladder: 50 mL autologous whole blood was collected and processed to prepare PRP (10 mL injection solution), injected at 2
Botulinum Toxin Group:Multisite bladder wall injection of botulinum toxin type A: 100 U botulinum toxin dissolved in 10 mL normal saline, injected at 20 sites identical to those used in the PRP group.
Sponsors
Gongli Hospital, Shanghai
Eligibility
Sex/Gender
All
Age
45 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age range of 45-65 years old, male or female not limited; 2. Meets the clinical diagnostic criteria for chronic cystitis (persistent lower urinary tract symptoms>6 weeks, excluding infection/tumor); 3. The patient's last water dilation treatment has been more than 3 months, and the last water dilation indicates a bladder capacity between 100-350ml; 4. Pain score>4 points; 5. Willing to participate in this study and sign an informed consent form
Exclusion criteria
Exclusion criteria: 1. Serious underlying diseases, including: (1) hypertension with systolic blood pressure >= 160 mmHg or systolic blood pressure >= 110 mmHg; (2) Diabetes (fasting blood glucose >= 10 mmol/L) or poor blood glucose control; (3) Respiratory system disorders, with normal oxygen saturation below 95% or moderate to severe ventilation/diffusion dysfunction; (4) T-cell lymphoma leading to systemic immune disorders; (5) Currently using anticoagulants or antiplatelet drugs; (6) There are other serious illnesses that result in insufficient physical strength to climb three floors on their own. 2. Urinary system diseases, including: (1) bladder or ureteral stones; (2) Recent (within 3 months) urinary tract infections; (3) Other pathological changes in the bladder, such as benign or malignant tumors of the bladder, urethral diverticulum, etc. 3. Other treatment influencing factors: (1) Platelet count < 100 × 10^9/L, hemoglobin < 100 g/L; (2) History of allergies to bladder injection therapy; (3) Received bladder botulinum toxin injection treatment within the past 6 months. 4. Pregnant or lactating women 5. Patients with mental illness, cognitive impairment, or inability to understand and comply with research requirements. 6. Other diseases that cannot accept platelet apheresis. 7. It is expected that data collection will not be completed during the follow-up period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PUF(Pelvic Pain and Urgency/Frequency Symptom Scale); | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS(Visual Analogue Scale for Pain);Functional bladder capacity(FBC);Average number of urinations per 24 hours;GRA(Interstitial Cystitis Problem Index Score);SAS(Self-Rating Anxiety Scale); | — |
Countries
China
Contacts
Public ContactLü Jianwei
Gongli Hospital, Shanghai
Outcome results
None listed